Skip to main content

Table 2 Clinical characteristics of PCa patients (Cohort 2)a and the correlation with GM+CTCs and total CTCs

From: Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Clinical characteristics

GM+CTCs

Total CTCs

Subgroup

Range

n (Percentage)

P/Nb

P

P/N

P

Age (years)

48–86

  

0.770

 

>  0.999

  ≤ 70

 

27 (50.0%)

9/18

 

15/12

 

  > 70

 

27 (50.0%)

8/19

 

15/12

 

Gleason score

6–9

  

0.099

 

0.013*

  ≤ 7

 

28 (51.9%)

6/22

 

11/17

 

  ≥ 8

 

26 (48.1%)

11/15

 

19/7

 

Clinical Stage

NA

  

0.003*

 

< 0.001*

 I + II

 

24 (44.4%)

2/22

 

7/17

 

 III + IV

 

30 (55.6%)

15/15

 

23/7

 

Metastasis

NA

  

0.002*

 

0.007*

 No

 

25 (46.3%)

2/23

 

9/16

 

 Yes

 

29 (53.7%)

15/14

 

21/8

 

tPSA (ng/mL)

0.01–6000.0

  

0.003*

 

0.017*

  ≤ 20

 

24 (44.4%)

2/22

 

9/15

 

  > 20

 

30 (55.6%)

15/15

 

21/9

 

fPSA/tPSA

2.24–50.68

  

0.965

 

0.322

  ≤ 15%

 

32 (59.3%)

10/22

 

16/16

 

  > 15%

 

22 (40.7%)

7/15

 

14/8

 

ALP (U/L)

44–718

  

0.200

 

0.808

  ≤ 90

 

26 (48.1%)

6/20

 

14/12

 

  > 90

 

28 (51.9%)

11/17

 

16/12

 

Hb (g/L)

71–162

  

0.507

 

0.625

  ≤ 120

 

25 (46.3%)

9/16

 

13/12

 

  > 120

 

29 (53.7%)

8/21

 

17/12

 
  1. *P < 0.05
  2. aCohort 2 includes 54 patients pathologically diagnosed with prostate cancer
  3. bP: positive; N: negative. The positive criterion of CTCs test is ≥3/5 mL